Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 3/20 | 0.36 |
| ▸ | METAP2 | P50579 | 2/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | CD38 | P28907 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL35211499 | 0.76 | TRPA1 (0.37) | METAP2 | |
| SCHEMBL35211291 | 0.75 | MAT2A (0.34) | IDO1TDO2ACACBMAPK1CD38 | |
| SCHEMBL20489085 | 0.73 | NOS1 (0.40) | NOS1METAP2CSNK2A1DYRK1AAXL | |
| SCHEMBL17099469 | 0.73 | NOS1 (0.41) | NOS1METAP2CSNK2A1DYRK1AAXL | |
| SCHEMBL35211261 | 0.71 | DYRK1A (0.40) | NOS1DYRK1AMAPTMAPK1 | |
| SCHEMBL31206793 | 0.69 | NOS1 (0.41) | NOS1METAP2CSNK2A1DYRK1AAXL | |
| SCHEMBL25204558 | 0.69 | AXL (0.44) | NOS1METAP2CSNK2A1DYRK1AAXL | |
| SCHEMBL3594308 | 0.66 | GABRA1 (0.42) | NOS1METAP2CSNK2A1DYRK1AAXL | |
| SCHEMBL14500106 | 0.62 | NOS1 (0.50) | NOS1METAP2CSNK2A1DYRK1AAXL | |
| SCHEMBL31472072 | 0.62 | NOS1 (0.46) | NOS1METAP2CSNK2A1DYRK1AAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125375-A1 | SUBSTITUTED 1H-PYRAZOLO-PYRIDINE AND -PYRIMIDINE COMPOUNDS | PFIZER INC. (US) | 2026-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125375-A1 | SUBSTITUTED 1H-PYRAZOLO-PYRIDINE AND -PYRIMIDINE COMPOUNDS | CCR1, CCR6, CCRL2 | NOS1 3221/4885METAP2 3861/4885CSNK2A1 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.